EN
Cannabidiol (CBD) is a major non-psychotropic compound of cannabis that has been reported to exert neuroprotective, antipsychotic and anxiolytic effects. CBD has promising anti-inflammatory properities, but despite therapeutic potential its mechanisms of action remain poorly understood. Our previous study revealed decrease in number of lymphocytes B and T in peripheral blood following repeated CBD administration. The present study aimed to assess effects of repeated administration of CBD on distribution of lymphocyte subsets in the spleen and the involvement of CB2 receptors. Adult male Wistar rats (n=35, 10 weeks of age at the start of study) received intraperitoneal injections of CBD at a dose of 5 mg/kg/day, or the vehicle, for 14 consecutive days. Total and relative numbers of lymphocyte T (T CD4+, and T CD8+), B, NK subsets were determined by flow cytometry. The selective CB2 receptor antagonist AM630 (1 mg/kg) was administered 15 min before CBD (or the vehicle) in order to block CB2 receptors. Repeated administration of CBD decreased total leukocyte number resulting from decreased numbers of lymphocytes B and T (both T CD8+ and T CD4+) in the spleen. Pretreatment with CB2 receptor antagonist partially inhibited CBD-induced decrease in lymphocyte number that was most pronounced in case of T CD8+ lymphocytes. AM630 itself produced slight decline in lymphocyte number that did not reach statistical significance. Observed effects were accompanied by a decrease in body weight gain, which was prevented by pretreatment with CB2 antagonist. The results indicate that CBD reduces lymphocyte number in the spleen, as it does in peripheral blood and that CBD has ability to affect the lymphocyte number via CB2 receptor.